Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

European Partners Combine to Bring Therapeutic Antibody to Market

By BiotechDaily International staff writers
Posted on 15 Aug 2013
Print article
Two European biotechnology companies have agreed to collaborate to complete development and commence marketing of a novel therapeutic antibody that targets the GD2 antigen, which is abundantly expressed on neuroblastoma cells.

Neuroblastoma is a cancer of the sympathetic nervous system that accounts for about 7% of all childhood cancers and 10% to 15% of all childhood cancer deaths.

Apeiron Biologics AG (Vienna, Austria), a biotech company focused on immunologic and biologic therapies against cancer, has agreed to a joint project with Rentschler Biotechnologie GmbH (Laupheim, Germany), a full service biopharmaceutical contract manufacturer, to complete development of the chimeric APN311 antibody for advanced clinical studies and then to manufacture it under full GMP compliance.

Per the agreement, Apeiron will receive access to experienced teams, appropriate mammalian cell culture capacity for clinical phase I to III trials, commercial production, fill and finish services as well as a scientifically driven, and responsive project management. The manufacturing process, validation, and regulatory affairs will be transferred to Rentschler.

Hans Loibner, CEO of Apeiron Biologics, said, "We are happy to have identified Rentschler as a professional contract manufacturer and consider this collaboration as a distinct value increase for our project APN311, which is also acknowledged in discussions with existing and potential partners. This decision resolved a significant hurdle in our effort to make this therapy available as soon as possible. I am very much looking forward to a fruitful collaboration."

"We are very excited to contribute our expertise to meet the truly challenging timeline of this project which is so very important for children suffering from this life threatening disease," said Frank Ternes, chief business officer at Rentschler. "We are confident that this cooperative atmosphere will continue to grow and mature over the course of the entire project, and ensure the success of this partnership."

Related Links:
Apeiron Biologics AG
Rentschler Biotechnologie GmbH



Print article

Channels

Drug Discovery

view channel
Image: A scanning electron microscope (SEM) image of methicillin-resistant Staphylococcus aureus bacteria (Photo courtesy of the CDC).

Drug Combination Cures MRSA Infection While Preventing Development of Resistance

Treatment with a combination comprising the well-known antibiotic cefdinir and the experimental drug TXA709 cured mice of drug-resistant staphylococcal infections while reducing the development of resistance.... Read more

Biochemistry

view channel
Image: A space-filling model of the anticonvulsant drug carbamazepine (Photo courtesy of Wikimedia Commons).

Wastewater May Contaminate Crops with Potentially Dangerous Pharmaceuticals

Reclaimed wastewater used to irrigate crops is contaminated with pharmaceutical residues that can be detected in the urine of those who consumed such produce. Investigators at the Hebrew University... Read more

Lab Technologies

view channel
Image: A three-dimensional printer adapted for stem cell production (Photo courtesy of Nano Dimension).

Israeli Developers Demonstrate Prototype Three-Dimensional Bioprinter

Two Israeli companies have combined efforts in the development of three-dimensional printer technology for the production of stem cells. The three-dimensional print electronics developer Nano Dimension... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.